1. [CASE 1 — QUESTION 1]
A 57-year-old man (initials R.K.) is newly diagnosed with diffuse large B-cell lymphoma and is scheduled to begin R-CHOP chemotherapy, which includes rituximab, an anti-CD20 monoclonal antibody. Pre-chemotherapy screening shows hepatitis B surface antigen positive, hepatitis B e antigen negative, HBV DNA 2,400 IU/mL, and normal aminotransferases. He has no symptoms of liver disease. The oncology team asks how to manage his hepatitis B before chemotherapy begins. What is the most appropriate action?
A) Withhold antiviral therapy and monitor aminotransferases during chemotherapy, treating only if they rise
B) Begin prophylactic nucleos(t)ide analogue therapy (tenofovir alafenamide or entecavir preferred) before starting chemotherapy and continue it after completion, because a surface antigen positive patient receiving anti-CD20 therapy is at high risk of reactivation
C) Administer a single dose of hepatitis B immune globulin at the first chemotherapy cycle
D) Defer any antiviral treatment because the baseline HBV DNA is low
E) Begin pegylated interferon-alpha for the duration of chemotherapy
ANSWER: B
Rationale:
A hepatitis B surface antigen positive patient about to receive a high-risk regimen such as rituximab-containing chemotherapy requires prophylactic nucleos(t)ide analogue therapy (tenofovir alafenamide or entecavir preferred), started before chemotherapy and continued afterward, because reactivation in this setting can progress to acute liver failure and death.
Option A: Option A is incorrect and unsafe because waiting for aminotransferases to rise forfeits the protective purpose of prophylaxis.
Option C: Option C is incorrect because immune globulin is not used to prevent reactivation in a chronically infected patient.
Option D: Option D is incorrect because reactivation risk in a surface antigen positive patient on anti-CD20 therapy is high regardless of a modest baseline HBV DNA.
Option E: Option E is incorrect because pegylated interferon is not used as reactivation prophylaxis and is poorly tolerated alongside chemotherapy.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. R.K. is started on prophylactic entecavir before chemotherapy. A trainee asks why rituximab-based therapy in particular carries such a high reactivation risk. Which explanation is correct?
A) Rituximab directly injures hepatocytes through a toxic metabolite, independent of the patient's hepatitis B status
B) Rituximab cures hepatitis B by depleting the B cells that harbor the virus, so reactivation reflects rebound after cure
C) Rituximab increases hepatic CYP2E1 activity, generating reactive metabolites that damage the liver
D) Anti-CD20 therapy depletes B cells and disrupts the immune surveillance that normally controls hepatitis B, allowing the virus to replicate unchecked; the resulting reactivation can cause severe hepatitis and acute liver failure
E) Rituximab lowers serum bile acids, which paradoxically stimulates hepatitis B replication
ANSWER: D
Rationale:
Anti-CD20 agents such as rituximab deplete B cells and disrupt the immune control that normally suppresses hepatitis B replication. When that surveillance is lost, the virus replicates unchecked, and the ensuing reactivation can produce severe hepatitis and acute liver failure — which is why prophylaxis is mandatory in this setting.
Option A: Option A is incorrect because the danger arises from loss of immune control of latent virus, not a direct hepatotoxic metabolite of rituximab.
Option B: Option B is incorrect because rituximab does not cure hepatitis B; by suppressing immunity it raises reactivation risk.
Option C: Option C is incorrect because CYP2E1 induction with reactive-metabolite injury describes acetaminophen toxicity, not the rituximab reactivation mechanism.
Option E: Option E is incorrect because the bile-acid effect described belongs to bulevirtide's pharmacology and does not drive hepatitis B reactivation.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. R.K. completes six cycles of R-CHOP while on entecavir. The team asks how long prophylaxis should continue and what monitoring is needed. Which approach is most appropriate?
A) Continue entecavir for a defined period after completing immunosuppression rather than stopping it with the last chemotherapy cycle, with monitoring of HBV DNA and aminotransferases, because reactivation flares can occur after immunosuppression ends as immune function returns
B) Stop entecavir on the day of the final chemotherapy cycle, since reactivation risk ends immediately when chemotherapy stops
C) Stop entecavir and switch to pegylated interferon to consolidate the response
D) Discontinue all monitoring once chemotherapy is complete, because prophylaxis fully eradicated the virus
E) Continue entecavir indefinitely with no need for any HBV DNA or aminotransferase monitoring
ANSWER: A
Rationale:
Reactivation can occur not only during immunosuppression but also after it ends, as immune reconstitution drives an inflammatory flare against infected hepatocytes; prophylaxis is therefore continued for a defined period beyond the last immunosuppressive dose, with ongoing HBV DNA and aminotransferase monitoring.
Option B: Option B is incorrect because reactivation risk does not end the moment chemotherapy stops; flares can follow immune recovery.
Option C: Option C is incorrect because pegylated interferon is not used to consolidate prophylaxis and is poorly suited here.
Option D: Option D is incorrect because prophylaxis suppresses but does not eradicate the virus, so monitoring must continue.
Option E: Option E is incorrect because, while a defined continuation period is appropriate, monitoring of HBV DNA and aminotransferases is still required rather than abandoned.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. After prophylaxis is eventually stopped, R.K. asks whether the entecavir cleared his hepatitis B for good. Which statement best explains why he was not cured by the prophylactic course?
A) The entecavir eradicated the virus, and any later positivity would represent reinfection rather than persistence
B) Entecavir cured the infection by eliminating circulating virus, so no reservoir remains
C) Nucleos(t)ide analogues suppress viral replication but do not eliminate the covalently closed circular DNA (cccDNA) reservoir in hepatocyte nuclei, so the infection persists and can reactivate despite effective suppression
D) Entecavir works only during chemotherapy and has no antiviral effect at other times
E) The infection was cured because his aminotransferases remained normal throughout treatment
ANSWER: C
Rationale:
Nucleos(t)ide analogues such as entecavir potently suppress replication but do not clear the cccDNA template that persists in hepatocyte nuclei; because this reservoir remains, the infection is controlled rather than cured and can reactivate after suppression is withdrawn.
Option A: Option A is incorrect because the virus is not eradicated; later viremia reflects persistence from the cccDNA reservoir, not reinfection.
Option B: Option B is incorrect because entecavir does not eliminate the reservoir, so a latent source remains.
Option D: Option D is incorrect because entecavir is antivirally active whenever it is taken, not only during chemotherapy.
Option E: Option E is incorrect because normal aminotransferases reflect absence of active necroinflammation, not viral cure.
5. [CASE 2 — QUESTION 1]
A 66-year-old woman (initials M.T.) with chronic hepatitis B (e antigen negative, HBV DNA 55,000 IU/mL) needs to start oral antiviral therapy. Her estimated glomerular filtration rate is 25 mL/min/1.73m2, and bone densitometry shows osteopenia. She has no prior antiviral exposure and takes no interacting medications. Which first-line agent is most appropriate?
A) Tenofovir disoproxil fumarate, because it is the tenofovir prodrug with the least renal toxicity
B) Lamivudine, because its renal safety outweighs its low resistance barrier in this patient
C) Pegylated interferon-alpha, because her comorbidities favor finite injectable therapy
D) Entecavir at a standard unadjusted dose, because entecavir clearance is independent of renal function
E) Tenofovir alafenamide, because its lower systemic tenofovir exposure gives a better renal and bone safety profile and it is preferred in renal impairment and low bone density
ANSWER: E
Rationale:
This patient has both renal impairment and low bone density — the two settings in which tenofovir alafenamide is specifically preferred over tenofovir disoproxil fumarate. Tenofovir alafenamide achieves equivalent antiviral effect with substantially lower systemic tenofovir exposure, reducing the exposure-dependent renal tubular and bone toxicities.
Option A: Option A is incorrect because tenofovir disoproxil fumarate is the prodrug with the greater renal toxicity, not the least.
Option B: Option B is incorrect because lamivudine's low resistance barrier makes it a poor first-line choice and its selection is not justified by renal safety.
Option C: Option C is incorrect because pegylated interferon has a heavy adverse-effect burden and is not selected on renal or bone grounds, and it is poorly suited to an older patient with comorbidity.
Option D: Option D is incorrect because entecavir does require dose reduction in renal impairment, so a standard unadjusted dose is inappropriate at this estimated glomerular filtration rate.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. M.T. is started on tenofovir alafenamide 25 mg daily. She notes that her friend takes tenofovir disoproxil fumarate at 300 mg daily and asks how a dose roughly ten times smaller can work as well. Which explanation is correct?
A) Tenofovir alafenamide is a far more potent inhibitor of reverse transcriptase per molecule, so less drug is intrinsically needed at the enzyme
B) Tenofovir alafenamide is more stable in plasma and delivers tenofovir efficiently into hepatocytes, so a much lower dose achieves equivalent intracellular antiviral concentrations while producing lower systemic tenofovir exposure
C) Tenofovir alafenamide is dosed lower only because it is more expensive, not because of any pharmacologic difference
D) Tenofovir alafenamide bypasses conversion to tenofovir entirely and acts through a different active compound
E) The lower dose reflects reduced oral bioavailability, so less drug actually reaches the circulation in active form
ANSWER: B
Rationale:
Tenofovir alafenamide is more stable in plasma than tenofovir disoproxil fumarate and delivers tenofovir preferentially into hepatocytes, so a much lower oral dose produces equivalent intracellular (and thus antiviral) tenofovir concentrations while keeping systemic tenofovir exposure low — the basis for both equal efficacy and improved safety.
Option A: Option A is incorrect because the active moiety is the same tenofovir at the enzyme; the difference is targeted delivery, not greater intrinsic potency at reverse transcriptase.
Option C: Option C is incorrect because the lower dose reflects pharmacology, not cost.
Option D: Option D is incorrect because tenofovir alafenamide is a tenofovir prodrug and does act through tenofovir, not a different compound.
Option E: Option E is incorrect because the lower dose reflects efficient hepatocyte delivery, not poor bioavailability reducing active drug delivery.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. Years earlier, before this presentation, M.T. had actually received lamivudine for a period that was not initially disclosed. After a later switch to entecavir for convenience, her HBV DNA rises from undetectable to 6,500 IU/mL despite confirmed adherence, and genotypic testing reveals M204V/M204I mutations. What is the most appropriate management?
A) Switch to tenofovir (tenofovir disoproxil fumarate or tenofovir alafenamide), because the lamivudine-associated M204V/M204I mutations cause cross-resistance that undermines entecavir, whereas tenofovir retains activity
B) Increase entecavir to 2 mg daily to overcome the M204 mutations
C) Re-add lamivudine to entecavir to restore susceptibility
D) Continue entecavir unchanged, since the DNA rise is laboratory variation
E) Switch to pegylated interferon, since all oral agents are now ineffective
ANSWER: A
Rationale:
The lamivudine resistance mutations M204V/M204I produce cross-resistance that markedly reduces entecavir efficacy in lamivudine-experienced patients, explaining the virologic breakthrough despite adherence. Tenofovir retains full activity against lamivudine-resistant virus and is the correct switch.
Option B: Option B is incorrect because dose escalation does not overcome M204-mediated resistance.
Option C: Option C is incorrect because re-adding lamivudine cannot restore susceptibility in a virus already carrying lamivudine resistance mutations.
Option D: Option D is incorrect because a confirmed rise to 6,500 IU/mL with documented resistance mutations is virologic breakthrough, not laboratory variation.
Option E: Option E is incorrect because oral agents are not uniformly ineffective; tenofovir remains effective, so interferon is unnecessary.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. M.T. is now on tenofovir and is started on several new medications for unrelated conditions, including a statin and an antihypertensive. She worries about drug interactions with her hepatitis B therapy. Which statement is correct regarding the interaction profile of the preferred nucleos(t)ide analogues?
A) Tenofovir strongly inhibits CYP3A4, so all co-administered drugs require dose reduction
B) Tenofovir is a potent enzyme inducer that will render her statin subtherapeutic
C) The preferred nucleos(t)ide analogues require routine therapeutic drug monitoring because of unpredictable interactions
D) The preferred nucleos(t)ide analogues have minimal drug-interaction profiles because they are not metabolized by cytochrome P450 enzymes, in contrast to the protease inhibitor-containing hepatitis C regimens, which carry substantial CYP3A4-based interactions
E) Tenofovir cannot be co-administered with any statin because of a shared renal transporter that causes toxicity
ANSWER: D
Rationale:
The preferred hepatitis B nucleos(t)ide analogues are not metabolized by cytochrome P450 enzymes and therefore have minimal drug-interaction profiles — a useful contrast with the hepatitis C protease inhibitor-containing regimens, whose CYP3A4 and transporter involvement drives clinically important interactions.
Option A: Option A is incorrect because tenofovir does not strongly inhibit CYP3A4.
Option B: Option B is incorrect because tenofovir is not a potent enzyme inducer and will not render a statin subtherapeutic.
Option C: Option C is incorrect because these agents do not require routine therapeutic drug monitoring for interactions.
Option E: Option E is incorrect because there is no shared-transporter prohibition against co-administering tenofovir with statins as described.
9. [CASE 3 — QUESTION 1]
A 49-year-old man (initials D.P.) has chronic hepatitis C, genotype 3, with compensated cirrhosis (Child-Pugh A). He is treatment-naive, has normal renal function, and takes no medications. He asks about a regimen that will work for his genotype. Which pan-genotypic first-line option and duration is appropriate?
A) Pegylated interferon plus ribavirin for 24 weeks, the most effective approach for genotype 3
B) An NS5A inhibitor alone for 8 weeks, since genotype 3 is highly susceptible to NS5A monotherapy
C) Sofosbuvir/velpatasvir for 12 weeks, a pan-genotypic regimen effective against genotype 3 including compensated cirrhosis
D) Sofosbuvir monotherapy for 12 weeks, since its high resistance barrier makes one agent sufficient
E) No therapy, since genotype 3 cirrhosis cannot achieve sustained virologic response
ANSWER: C
Rationale:
Sofosbuvir/velpatasvir is a pan-genotypic regimen active against genotype 3 — historically the most treatment-resistant genotype — and is appropriate for 12 weeks in compensated cirrhosis. With normal renal function and no interacting drugs, a sofosbuvir-containing regimen is suitable for this patient.
Option A: Option A is incorrect because interferon-based therapy is obsolete for genotype 3 given the efficacy and tolerability of direct-acting antivirals.
Option B: Option B is incorrect because NS5A inhibitors are never used as monotherapy owing to their low resistance barrier.
Option D: Option D is incorrect because sofosbuvir is not used as monotherapy; it is combined with at least one other class.
Option E: Option E is incorrect because genotype 3 cirrhosis can achieve high sustained virologic response rates with modern pan-genotypic regimens.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. Before D.P. starts therapy, medication reconciliation reveals he was recently started on amiodarone for atrial fibrillation, which his cardiologist wishes to continue. The sofosbuvir/velpatasvir plan is reconsidered. What is the most appropriate action?
A) Proceed with sofosbuvir/velpatasvir and add a beta-blocker to control any heart-rate effect
B) Proceed with sofosbuvir/velpatasvir after a single baseline electrocardiogram, with no further monitoring
C) Stop amiodarone the morning therapy begins, since the interaction resolves immediately on discontinuation
D) Withhold all hepatitis C treatment indefinitely because amiodarone precludes cure
E) Select a sofosbuvir-free regimen such as glecaprevir/pibrentasvir, because a sofosbuvir-containing regimen combined with amiodarone risks serious, potentially fatal symptomatic bradycardia
ANSWER: E
Rationale:
Amiodarone combined with a sofosbuvir-containing regimen risks serious, potentially fatal symptomatic bradycardia. With amiodarone continued, the appropriate action is to choose a sofosbuvir-free regimen such as glecaprevir/pibrentasvir, which avoids the interaction; glecaprevir/pibrentasvir is also pan-genotypic and active against genotype 3.
Option A: Option A is incorrect because adding a beta-blocker does not mitigate the bradycardia hazard and still pairs sofosbuvir with amiodarone.
Option B: Option B is incorrect because a single baseline electrocardiogram is inadequate; avoidance is preferred over light monitoring.
Option C: Option C is incorrect because amiodarone has an extremely long half-life (weeks), so same-day discontinuation does not promptly remove the risk.
Option D: Option D is incorrect because cure is readily achievable with a sofosbuvir-free regimen, so withholding therapy is unwarranted.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. D.P. is switched to glecaprevir/pibrentasvir. During further review, it emerges that he takes rifampin as part of treatment for latent tuberculosis. What is the concern, and the correct interpretation?
A) Rifampin inhibits the metabolism of the protease inhibitor, raising its levels to toxic concentrations and requiring a dose reduction
B) Rifampin, a strong inducer of CYP3A4 and P-glycoprotein, increases clearance of the glecaprevir component and lowers its plasma levels to subtherapeutic concentrations, risking virologic failure; strong inducers are an absolute contraindication with protease inhibitor-containing regimens
C) Rifampin and glecaprevir/pibrentasvir do not interact because the protease inhibitor is not a CYP3A4 substrate
D) Rifampin competes for renal excretion with the regimen, prolonging both drugs and improving cure rates
E) The combination causes glutathione-depletion hepatotoxicity analogous to acetaminophen injury
ANSWER: B
Rationale:
The NS3/4A protease inhibitor glecaprevir is a substrate of CYP3A4 and P-glycoprotein. Rifampin, a strong inducer of both, increases its clearance and lowers plasma levels to subtherapeutic concentrations, risking virologic failure and resistance — which is why strong inducers are an absolute contraindication with protease inhibitor-containing regimens.
Option A: Option A inverts the direction: rifampin is an inducer, lowering rather than raising drug levels.
Option C: Option C is incorrect because the protease inhibitor is indeed a CYP3A4 substrate, so the interaction is real.
Option D: Option D is incorrect because the mechanism is hepatic enzyme and transporter induction, not competition for renal excretion, and the effect is loss of efficacy.
Option E: Option E is incorrect because the interaction reduces drug exposure and does not cause glutathione-depletion hepatotoxicity, which is the acetaminophen mechanism.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. After the tuberculosis regimen is adjusted in coordination with his specialists so that therapy can proceed, D.P.'s remaining medications are reviewed. He takes rosuvastatin for hyperlipidemia. What is the most appropriate action regarding the statin during glecaprevir/pibrentasvir therapy?
A) Continue rosuvastatin unchanged, since statins do not interact with glecaprevir/pibrentasvir
B) Double the rosuvastatin dose because the regimen lowers statin exposure
C) Switch to high-dose atorvastatin with no dose limit
D) Stop rosuvastatin during glecaprevir/pibrentasvir therapy, because rosuvastatin is contraindicated with this regimen owing to markedly increased statin exposure (via inhibition of CYP3A4 and the OATP1B transporter) and consequent myopathy risk
E) Replace the statin with pegylated interferon to avoid the interaction
ANSWER: D
Rationale:
NS3/4A protease inhibitors raise statin exposure through inhibition of CYP3A4 and the hepatic uptake transporter OATP1B, increasing myopathy risk; with glecaprevir/pibrentasvir, rosuvastatin is contraindicated and should be stopped during therapy.
Option A: Option A is incorrect because a clinically important statin interaction does exist with this protease inhibitor-containing regimen.
Option B: Option B is incorrect because the regimen raises, not lowers, statin exposure, so increasing the dose would worsen toxicity.
Option C: Option C is incorrect because atorvastatin requires dose capping with this regimen, not unlimited high dosing.
Option E: Option E is incorrect because pegylated interferon is not a lipid-lowering agent and is not a substitute for a statin; the correct action is to hold the contraindicated statin.
13. [CASE 4 — QUESTION 1]
A 61-year-old man (initials J.L.) with end-stage renal disease on maintenance hemodialysis has chronic hepatitis C, genotype 1, without cirrhosis. He is treatment-naive and takes no interacting medications. Which regimen is most appropriate given his renal status?
A) Glecaprevir/pibrentasvir, because it contains no sofosbuvir and requires no dose adjustment in renal impairment, making it preferred in advanced chronic kidney disease including dialysis
B) Sofosbuvir/velpatasvir at full dose, because sofosbuvir is removed by dialysis and therefore safe
C) Sofosbuvir/velpatasvir with the sofosbuvir dose halved to account for metabolite accumulation
D) Pegylated interferon plus ribavirin, because direct-acting antivirals cannot be used in dialysis
E) Sofosbuvir monotherapy, because dialysis clears the inactive metabolite between sessions
ANSWER: A
Rationale:
Glecaprevir/pibrentasvir contains no sofosbuvir and requires no dose adjustment in renal impairment, making it the preferred pan-genotypic regimen for patients with advanced chronic kidney disease, including those on dialysis.
Option B: Option B is incorrect because sofosbuvir's inactive metabolite accumulates in severe renal impairment, and relying on dialysis removal is not the established approach.
Option C: Option C is incorrect because simple dose-halving of sofosbuvir is not the recommended strategy.
Option D: Option D is incorrect because effective oral direct-acting antivirals exist for dialysis patients, so interferon and ribavirin are unnecessary.
Option E: Option E is incorrect because sofosbuvir is not used as monotherapy, and metabolite accumulation makes a sofosbuvir-containing approach less suitable than a sofosbuvir-free regimen here.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. A trainee asks specifically why a sofosbuvir-containing regimen is avoided in J.L. rather than simply dialyzing the drug off. What is the correct pharmacologic basis?
A) Sofosbuvir is directly nephrotoxic and would worsen his already-absent renal function
B) Sofosbuvir cannot be given in dialysis because it is removed too rapidly to maintain antiviral levels
C) Sofosbuvir is eliminated renally as the inactive metabolite GS-331007, which accumulates significantly when the estimated glomerular filtration rate falls below 30 mL/min/1.73m2, so a sofosbuvir-free regimen is preferred in severe renal impairment
D) Sofosbuvir is hepatically cleared and has no relationship to renal function, so the concern is unfounded
E) Sofosbuvir induces CYP3A4 in the kidney, accelerating clearance of co-administered drugs
ANSWER: C
Rationale:
Sofosbuvir is eliminated renally as the inactive metabolite GS-331007, which accumulates significantly when the estimated glomerular filtration rate falls below about 30 mL/min/1.73m2; this accumulation is why a sofosbuvir-free regimen such as glecaprevir/pibrentasvir is preferred in severe renal impairment rather than relying on dialysis removal.
Option A: Option A is incorrect because the issue is metabolite accumulation, not direct nephrotoxicity.
Option B: Option B is incorrect because the concern is accumulation of the metabolite, not excessively rapid removal of the parent drug.
Option D: Option D is incorrect because sofosbuvir is not purely hepatically cleared; its metabolite is renally eliminated, so renal function is relevant.
Option E: Option E is incorrect because sofosbuvir does not induce renal CYP3A4; that mischaracterizes its pharmacology.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. J.L. completes glecaprevir/pibrentasvir, and twelve weeks after finishing treatment his hepatitis C RNA is undetectable. He asks what this result means for him. Which statement is correct?
A) It means his viral load has dropped by at least 12 percent, a partial response that requires further therapy
B) It represents sustained virologic response at 12 weeks (SVR12) — undetectable hepatitis C RNA 12 weeks after completing treatment — which is accepted as virologic cure in the vast majority of patients
C) It indicates he must continue treatment for another 12 weeks to consolidate the response
D) It confirms he is now immune to hepatitis C and cannot be reinfected
E) It means the virus has become dormant and is expected to relapse within a year
ANSWER: B
Rationale:
Undetectable hepatitis C RNA measured 12 weeks after completing treatment is sustained virologic response at 12 weeks (SVR12), the accepted definition of virologic cure; patients who reach SVR12 do not relapse virologically in the vast majority of cases.
Option A: Option A is incorrect because SVR12 is undetectable RNA, not a percentage reduction or a partial response.
Option C: Option C is incorrect because SVR12 is assessed after therapy is complete and does not signal a need to extend treatment.
Option D: Option D is incorrect because cure does not confer immunity; reinfection on re-exposure remains possible.
Option E: Option E is incorrect because SVR12 indicates durable cure, not impending relapse.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. During pre-treatment staging, liver elastography and imaging had in fact demonstrated previously unrecognized cirrhosis. Now cured (SVR12 achieved), J.L. asks whether he can stop his periodic liver cancer screening. What is the most appropriate counsel?
A) Stop screening now, because achieving SVR12 reverses cirrhosis and removes cancer risk
B) Reduce screening to once every five years, because cure lowers the risk to that of the general population
C) Replace imaging with annual aminotransferase testing alone, since normal enzymes exclude cancer
D) Stop screening and monitor only hepatitis C RNA, since detectable virus is the sole driver of cancer risk
E) Continue hepatocellular carcinoma surveillance, because although SVR12 is a durable cure that lowers cancer incidence, the residual cirrhosis continues to carry hepatocellular carcinoma risk even after the virus is cleared
ANSWER: E
Rationale:
Sustained virologic response reduces but does not eliminate hepatocellular carcinoma risk, and the structural cirrhosis persists after the virus is gone; ongoing hepatocellular carcinoma surveillance is therefore required in patients with cirrhosis after cure.
Option A: Option A is incorrect because cure does not fully reverse cirrhosis or abolish cancer risk.
Option B: Option B is incorrect because risk in a cirrhotic liver does not fall to general-population levels after cure, so a five-year interval is unsafe.
Option C: Option C is incorrect because normal aminotransferases do not exclude hepatocellular carcinoma and are not a substitute for imaging surveillance.
Option D: Option D is incorrect because hepatocellular carcinoma can arise in a cured but cirrhotic liver; active viral replication is not the sole driver of risk.
17. [CASE 5 — QUESTION 1]
A 36-year-old man (initials A.S.) who emigrated from a region where hepatitis D is endemic has chronic hepatitis B. Despite an HBV DNA of only 800 IU/mL, he has marked transaminase elevation and advancing fibrosis on elastography, with disease more severe than his HBV DNA would predict. What is the most appropriate next diagnostic step?
A) Repeat the HBV DNA in three months and take no further action now, given the low level
B) Begin empiric pegylated interferon without further testing, since severe hepatitis B warrants immediate therapy
C) Reassure him that this severity is typical of hepatitis B and pursue no further workup
D) Test for anti-hepatitis D virus antibody, because disease severity disproportionate to the HBV DNA level together with endemic-region origin is a classic clue to hepatitis D superinfection, which is frequently missed since anti-HDV is not part of the routine hepatitis B panel
E) Order a liver biopsy as the only way to explain the disease severity
ANSWER: D
Rationale:
Disease severity out of proportion to the HBV DNA level, combined with origin from an endemic region, is a classic clue to hepatitis D superinfection, which is frequently missed because anti-HDV testing is not part of the routine hepatitis B workup; the correct next step is to test for anti-HDV antibody.
Option A: Option A is incorrect because simply repeating HBV DNA ignores the most likely explanation and delays diagnosis.
Option B: Option B is incorrect because empiric interferon without establishing the diagnosis is inappropriate.
Option C: Option C is incorrect because this severity is not typical of low-level hepatitis B alone and warrants testing for hepatitis D.
Option E: Option E is incorrect because the diagnosis is made serologically and by HDV RNA, not primarily by biopsy.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. A.S.'s anti-hepatitis D virus antibody returns positive. The team must determine whether this represents active infection. Which statement correctly guides the next step and explains the underlying biology?
A) Confirm active infection with HDV RNA quantification, because anti-HDV IgG reflects exposure but does not distinguish active from resolved infection; hepatitis D requires hepatitis B surface antigen for assembly, so it occurs only in the setting of hepatitis B
B) A positive anti-HDV IgG alone confirms active replication, so no further testing is needed before treatment
C) Active hepatitis D can be present only if hepatitis B surface antigen is negative, so surface antigen status should be rechecked to exclude it
D) HDV RNA testing is unnecessary because hepatitis D resolves spontaneously once detected
E) Hepatitis D can establish infection independently of hepatitis B, so HBV status is irrelevant to interpretation
ANSWER: A
Rationale:
Anti-HDV IgG reflects exposure but does not distinguish active from resolved infection, so active hepatitis D must be confirmed with HDV RNA quantification; hepatitis D is a defective virus that requires hepatitis B surface antigen for assembly and therefore occurs only in patients with hepatitis B.
Option B: Option B is incorrect because anti-HDV IgG alone cannot establish active replication.
Option C: Option C inverts the biology: active hepatitis D requires the presence of hepatitis B surface antigen, so it coexists with detectable surface antigen rather than requiring its absence.
Option D: Option D is incorrect because hepatitis D does not reliably resolve spontaneously and HDV RNA testing is needed to confirm active infection.
Option E: Option E is incorrect because hepatitis D cannot establish infection independently of hepatitis B; its dependence on surface antigen is central to interpretation.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. Active hepatitis D is confirmed, and A.S. is started on bulevirtide. After several weeks his HDV RNA has declined only modestly and laboratory testing shows a rise in serum conjugated bile acids; he is concerned the drug is harming his liver or failing. Which interpretation is correct?
A) The slow HDV RNA decline confirms treatment failure and the rising bile acids indicate hepatotoxicity, so bulevirtide should be stopped
B) The findings indicate resistance has emerged, requiring an immediate switch to pegylated interferon
C) Both findings are expected: bulevirtide competitively blocks the sodium-taurocholate cotransporting polypeptide, so its virologic effect develops gradually as infected hepatocytes turn over, and blockade of that same bile-acid transporter produces a dose-dependent rise in conjugated bile acids that is pharmacodynamic rather than hepatotoxic
D) The bile-acid rise reflects glutathione depletion, the same mechanism as acetaminophen injury
E) The result indicates a dosing error, since correctly dosed bulevirtide eliminates HDV RNA within the first two weeks
ANSWER: C
Rationale:
Bulevirtide competitively blocks the sodium-taurocholate cotransporting polypeptide, the receptor used for both viral entry and hepatocyte bile-acid uptake. Because it prevents new cell entry rather than acting inside infected cells, its virologic effect develops gradually as infected hepatocytes turn over, and blockade of bile-acid uptake produces a dose-dependent rise in serum conjugated bile acids that is a pharmacodynamic marker of target engagement, not hepatotoxicity.
Option A: Option A is incorrect because the slow decline and bile-acid rise are both expected, not signs of failure or liver injury warranting cessation.
Option B: Option B is incorrect because a gradual decline does not indicate resistance.
Option D: Option D is incorrect because the bile-acid rise reflects transporter blockade, not glutathione depletion.
Option E: Option E is incorrect because the delayed kinetics are intrinsic to entry blockade, not evidence of a dosing error.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. While on bulevirtide, A.S. is also continued on a nucleos(t)ide analogue for his hepatitis B. He asks what role the hepatitis B drug plays in his hepatitis D. Which explanation is correct?
A) The nucleos(t)ide analogue directly and potently suppresses HDV RNA and is the main anti-HDV agent
B) The nucleos(t)ide analogue does not by itself meaningfully suppress HDV RNA, but it is indicated to control concurrent HBV replication and protect the liver, and by suppressing HBV it reduces the surface antigen substrate available for HDV virion production
C) The nucleos(t)ide analogue should be stopped during hepatitis D treatment because it accelerates HDV replication
D) The nucleos(t)ide analogue cures hepatitis D by eliminating the cccDNA on which HDV depends
E) The nucleos(t)ide analogue is interchangeable with bulevirtide and provides identical anti-HDV activity
ANSWER: B
Rationale:
Nucleos(t)ide analogues do not by themselves meaningfully suppress HDV RNA, but they are indicated to control concurrent HBV replication and protect the liver; because hepatitis D depends on hepatitis B surface antigen for assembly, suppressing HBV reduces the surface antigen substrate available for HDV virion production, so nucleos(t)ide analogue therapy serves as background therapy.
Option A: Option A is incorrect because nucleos(t)ide analogues do not directly suppress HDV RNA and are not the main anti-HDV agent.
Option C: Option C is incorrect because they are not stopped and do not accelerate HDV replication.
Option D: Option D is incorrect because nucleos(t)ide analogues do not eliminate cccDNA or cure hepatitis D.
Option E: Option E is incorrect because they are not interchangeable with bulevirtide, which is the entry inhibitor with direct anti-HDV activity.
21. [CASE 6 — QUESTION 1]
A 26-year-old woman (initials K.D.) presents to the emergency department reporting an intentional acetaminophen overdose approximately 14 hours earlier. She is nauseated with mild right upper quadrant tenderness. A serum acetaminophen level has been sent but is not yet back. What is the most appropriate immediate action?
A) Wait for the serum acetaminophen level before deciding whether to treat, since treatment at 14 hours is futile
B) Give activated charcoal as the definitive treatment, since it is now too late for the antidote
C) Administer oral N-acetylcysteine loading despite her nausea, since the oral route is always preferred
D) Discharge her with outpatient follow-up, since 14 hours without fulminant symptoms indicates minimal risk
E) Initiate intravenous N-acetylcysteine now without waiting for the acetaminophen level, because the history is consistent with a toxic ingestion and N-acetylcysteine still confers benefit at this time point
ANSWER: E
Rationale:
When the history is consistent with a toxic acetaminophen ingestion, intravenous N-acetylcysteine should be started promptly without waiting for the serum level; efficacy is greatest within roughly 8 to 10 hours but is reduced rather than lost at later time points, so delay forfeits benefit.
Option A: Option A is incorrect because waiting for the level delays therapy, and treatment at 14 hours is not futile.
Option B: Option B is incorrect because activated charcoal is most useful early after ingestion and is not the definitive antidote.
Option C: Option C is incorrect because oral loading is avoided in a nauseated or potentially encephalopathic patient owing to aspiration risk, and intravenous administration is appropriate.
Option D: Option D is incorrect and dangerous because the absence of fulminant symptoms at 14 hours does not exclude significant toxicity; hepatotoxicity characteristically evolves over the following days.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. K.D. is started on intravenous N-acetylcysteine. A student asks how the antidote actually protects the liver in acetaminophen overdose. Which explanation is correct?
A) In overdose, saturation of conjugation pathways shunts more acetaminophen through CYP2E1 to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione; N-acetylcysteine supplies cysteine, the rate-limiting substrate for glutathione synthesis, replenishing glutathione so residual NAPQI can be detoxified
B) N-acetylcysteine binds circulating acetaminophen directly and is excreted with it before any reactive metabolite forms
C) N-acetylcysteine neutralizes gastric acid, preventing further acetaminophen absorption
D) N-acetylcysteine completely inhibits CYP2E1, so no acetaminophen can be oxidized at all
In overdose, the glucuronidation and sulfation pathways saturate, shunting more acetaminophen through CYP2E1 to the reactive metabolite NAPQI, which depletes hepatic glutathione and then binds cellular proteins to cause necrosis. N-acetylcysteine supplies cysteine, the rate-limiting substrate for glutathione synthesis, replenishing glutathione so residual NAPQI can be detoxified.
Option B: Option B is incorrect because N-acetylcysteine acts mainly by replenishing glutathione, not by binding circulating acetaminophen for excretion.
Option C: Option C is incorrect because N-acetylcysteine is not an antacid and does not work by blocking absorption.
Option D: Option D is incorrect because it does not work by completely inhibiting CYP2E1.
Option E: Option E is incorrect because it does not act by accelerating renal excretion of intact acetaminophen.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. Over the next two days K.D. deteriorates: she develops grade III encephalopathy, her arterial pH is 7.25 after adequate fluid resuscitation, serum creatinine is 3.8 mg/dL, and prothrombin time exceeds 100 seconds. Which assessment and action is most appropriate?
A) These values are reassuring and indicate she is recovering, so transplant evaluation is unnecessary
B) Transplant listing should be deferred until she reaches grade IV encephalopathy, regardless of the other values
C) The King's College Criteria do not apply to acetaminophen-induced acute liver failure, so a different scoring system must be used before any referral
D) She meets the King's College Criteria for acetaminophen-induced acute liver failure — an arterial pH below 7.30 after resuscitation (and, separately, the triad of creatinine above 3.4 mg/dL, prothrombin time above 100 seconds, and grade III-IV encephalopathy) — which should prompt urgent listing for emergency liver transplantation
E) Her presentation argues against transplantation because acetaminophen toxicity always resolves with continued N-acetylcysteine
ANSWER: D
Rationale:
For acetaminophen-induced acute liver failure, the King's College Criteria identify high-risk patients by an arterial pH below 7.30 after resuscitation, or by all three of serum creatinine above 3.4 mg/dL, prothrombin time above 100 seconds, and grade III-IV encephalopathy. K.D. meets these criteria (both the pH threshold and the triad), which should prompt urgent listing for emergency liver transplantation.
Option A: Option A is incorrect because these values indicate severe, high-mortality disease, not recovery.
Option B: Option B is incorrect because waiting for grade IV encephalopathy forfeits the window for timely listing; she already meets criteria.
Option C: Option C is incorrect because the King's College Criteria include a specific acetaminophen set and do apply here.
Option E: Option E is incorrect because acetaminophen toxicity does not always resolve with N-acetylcysteine, and meeting these criteria signals the need for transplant evaluation.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. While awaiting a transplant decision, K.D. is managed in the intensive care unit, where she develops signs of cerebral edema and a vasodilated, high-output shock state. The team also reflects on how N-acetylcysteine would be used if her liver failure had instead been from a non-acetaminophen cause. Which statement correctly captures the appropriate intensive care pharmacology and the role of N-acetylcysteine in non-acetaminophen disease?
A) Cerebral edema is managed by withholding osmotherapy, and dopamine is the preferred first-line vasopressor while norepinephrine is avoided
B) Cerebral edema and intracranial hypertension are managed with osmotherapy (mannitol for intracranial pressure crises, hypertonic saline as prophylaxis targeting mild hypernatremia), norepinephrine is the first-line vasopressor for the vasodilated high-output state, and in non-acetaminophen acute liver failure intravenous N-acetylcysteine improves transplant-free survival with greatest benefit in early-grade (I-II) encephalopathy
C) Lactulose dosed to aggressive catharsis is the proven first-line measure that reduces mortality, and N-acetylcysteine has no role in non-acetaminophen disease
D) Stress ulcer prophylaxis should be withheld because acid suppression precipitates encephalopathy, and norepinephrine is contraindicated
E) N-acetylcysteine benefits non-acetaminophen acute liver failure most in advanced grade III-IV encephalopathy, and cerebral edema requires no specific pharmacologic management
ANSWER: B
Rationale:
In acute liver failure, cerebral edema and intracranial hypertension are managed with osmotherapy — mannitol for intracranial pressure crises and hypertonic saline as prophylaxis targeting a mildly elevated serum sodium — and norepinephrine is the first-line vasopressor for the vasodilated, high-output hemodynamic profile. In non-acetaminophen acute liver failure, intravenous N-acetylcysteine improves transplant-free survival, with benefit concentrated in early-grade (I-II) encephalopathy.
Option A: Option A is incorrect because osmotherapy is a mainstay rather than withheld, and norepinephrine — not dopamine — is first-line.
Option C: Option C is incorrect because lactulose has limited evidence and aggressive catharsis is harmful, and N-acetylcysteine does have a role in non-acetaminophen disease.
Option D: Option D is incorrect because stress ulcer prophylaxis is standard and norepinephrine is first-line, not contraindicated.
Option E: Option E inverts the encephalopathy relationship: the N-acetylcysteine benefit is greatest in early-grade (I-II), not advanced (III-IV), encephalopathy, and cerebral edema does require specific management.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.